A Preliminary Study of CA15-3, c-erbB-2, Epidermal Growth Factor Receptor, Cathepsin-D, and p53 in Saliva Among Women with Breast Carcinoma

Streckfus, Charles F.; Bigler, Lenora; Tucci, Michelle; Thigpen, J.T.

doi:10.3109/07357900009038240

Cited by 145 publications

(113 citation statements)

References 18 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Secreted pCD was demonstrated by immunofluorescence in tissue section, and by ELISA in tissue culture supernatants, carcinoma cytosols, saliva, 62 or nipple aspirates of both normal and carcinoma tissues (for review, see Ref. [46]).…”

Section: Discussionmentioning

confidence: 99%

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

2002

View full text Add to dashboard Cite

Procathepsin D (pCD) is a major secreted glycoprotein in some human breast and other cancer cell lines. Several groups proposed that pCD served as a growth factor for these cell lines. Secreted pCD has been demonstrated in tissue section, tissue culture supernatants, carcinoma cytosols, and nipple aspirates. Moreover, several clinical studies suggested a potential role for this molecule in metastasis because its concentration in primary tumors correlated with an increased incidence of tumor metastases. In this paper, the effects of pCD were evaluated by proliferation in vitro and by mouse studies in vivo. Subsequent flow cytometry experiments showed the specificity of pCD binding to cancer cells. Cell cultivation showed that addition of either pCD or its activation peptide stimulates growth of cancer cells. These effects can be inhibited both in vitro and in vivo by anti-pCD antibodies. In addition, production of pCD can be inhibited by specifically designed ribozymes. This paper is focused on mitogenic effects of pCD, which seem to involve interaction of the activation peptide with as yet unidentified receptor. Different mechanisms by which pCD could promote development and spread of cancer cells are discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

2002

View full text Add to dashboard Cite

show abstract

“…However, while low levels of CA15-3 were also detected in the saliva and serum of healthy individuals, erb was not detected in healthy subjects and thus appears to hold greater promise for the early screening and detection of breast cancer (Streckfus et al ., 2000).…”

Section: Malignancymentioning

confidence: 99%

The Diagnostic Applications of Saliva— A Review

Kaufman

Lamster

2002

Critical Reviews in Oral Biology & Medicine

804

618

View full text Add to dashboard Cite

This review examines the diagnostic application of saliva for systemic diseases. As a diagnostic fluid, saliva offers distinctive advantages over serum because it can be collected non-invasively by individuals with modest training. Furthermore, saliva may provide a cost-effective approach for the screening of large populations. Gland-specific saliva can be used for diagnosis of pathology specific to one of the major salivary glands. Whole saliva, however, is most frequently used for diagnosis of systemic diseases, since it is readily collected and contains serum constituents. These constituents are derived from the local vasculature of the salivary glands and also reach the oral cavity via the flow of gingival fluid. Analysis of saliva may be useful for the diagnosis of hereditary disorders, autoimmune diseases, malignant and infectious diseases, and endocrine disorders, as well as in the assessment of therapeutic levels of drugs and the monitoring of illicit drug use.

show abstract

“…Saliva proteins may have diagnostic value for human oral and systemic diseases. For instance, the soluble fragments of the c-erbB-2 oncogene and CA 15-3 were found significantly up-regulated in the saliva samples of breast cancer patients than in those of healthy controls and patients with benign tumors [385,386]. Elevated levels of salivary CEA, defensin-1, TNF-alpha, IL-1, 6 and 8, and CD44 were detected in patients of oral cancer [387][388][389][390][391][392][393].…”

Section: Application To Human Disease Detectionmentioning

confidence: 99%

Human body fluid proteome analysis

2006

View full text Add to dashboard Cite

The focus of this article is to review the recent advances in proteome analysis of human body fluids, including plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, and amniotic fluid, as well as its applications to human disease biomarker discovery. We aim to summarize the proteomics technologies currently used for global identification and quantification of body fluid proteins, and elaborate the putative biomarkers discovered for a variety of human diseases through human body fluid proteome (HBFP) analysis. Some critical concerns and perspectives in this emerging field are also discussed. With the advances made in proteomics technologies, the impact of HBFP analysis in the search for clinically relevant disease biomarkers would be realized in the future.

show abstract

A Preliminary Study of CA15-3, c-erbB-2, Epidermal Growth Factor Receptor, Cathepsin-D, and p53 in Saliva Among Women with Breast Carcinoma

Cited by 145 publications

References 18 publications

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors

The Diagnostic Applications of Saliva— A Review

Human body fluid proteome analysis

Contact Info

Product

Resources

About